Mission Statement, Vision, & Core Values (2026) of Keymed Biosciences Inc.

Keymed Biosciences Inc. (2162.HK) stands at the intersection of ambitious science and real-world impact, driven by a mission to deliver novel peptide- and biologic-based therapies for metabolic, oncologic and autoimmune diseases-backed by a diversified pipeline of over 10 drug candidates and a fully integrated R&D-to-manufacturing platform; its flagship IL-4Rα antibody Stapokibart has already secured approvals for adult atopic dermatitis, chronic rhinosinusitis with nasal polyps and seasonal allergic rhinitis, while the company doubled down on innovation with RMB 500 million invested in R&D in 2022-a 42% increase year‑on‑year-and a separate recorded R&D outlay of $35 million in 2022 (a 15% rise) that underscores Keymed's patient‑centric, integrity‑focused culture and vision to pioneer affordable, world‑competitive treatments through collaboration, adaptability and cutting‑edge translational science.

Keymed Biosciences Inc. (2162.HK) - Intro

• Mission: Deliver affordable, high-quality biologic therapies that address urgent unmet medical needs for patients in China and globally, accelerating access through integrated R&D-to-manufacturing capabilities.
• Vision: To be a leading developer of novel biologics that transform standards of care in oncology and immune-mediated diseases by combining scientific rigor with scalable, cost-effective production.
• Core values:
  • Patient centricity - prioritize clinical impact and accessibility.
  • Scientific excellence - rigorous target validation and translational research.
  • Innovation and agility - pursue novel modalities (ADCs, bispecifics) and clear go-to-clinic paths.
  • Operational integrity - integrated platform from discovery to GMP manufacturing.
  • Collaborative partnerships - academia, CROs, and strategic investors to accelerate development.

• Strategic priorities:
  • Advance clinical-stage candidates to regulatory milestones and broaden indications for approved assets (e.g., Stapokibart).
  • Invest in biologics platform scalability to reduce cost of goods and improve patient access.
  • Expand partnerships for global development and commercialization to bring therapies beyond China.

Keymed Biosciences Inc. (2162.HK) - Overview

• Discover, develop, and commercialize novel peptide-based treatments for metabolic disorders.
• Advance therapeutic innovation while ensuring safety, efficacy, and accessibility for patients in need.
• Center all activities on improving patient health outcomes through integrity, collaboration, and evidence-based research.

• R&D intensity: reported R&D spending of $35 million in 2022, a 15% increase versus 2021.
• Pipeline breadth: a robust portfolio of over 10 drug candidates across preclinical and clinical stages.
• Patient-centric development: clinical programs designed to prioritize meaningful endpoints for metabolic disease populations.

• Push the boundaries of scientific knowledge in peptide therapeutics and metabolic disease biology.
• Foster cross-disciplinary collaboration with academic partners, clinical investigators, and industry consortia.
• Operate with transparency and ethical standards to accelerate access to treatments.

• Patient first - aligning programs and endpoints to patient needs and outcomes.
• Scientific excellence - rigorous preclinical and clinical evaluation of peptide modalities.
• Collaboration - active partnerships to accelerate development and broaden access.
• Integrity - ethical conduct in research, trials, and commercialization.

Keymed Biosciences Inc. (2162.HK) - Mission Statement

• Advance metabolic peptide therapeutics to meet global unmet medical needs.
• Scale and strengthen technology platforms to support a robust R&D pipeline for the next 10 years.
• Deliver world-competitive, high-quality, and affordable therapies to patients.
• Maintain sustained investment in research and development as the core growth engine.

Keymed's vision is backed by material investment: R&D expenditure reached RMB 500 million in 2022, representing a 42% year-over-year increase from 2021 (RMB ~352.11 million).

• Focus areas: metabolic disease peptides, platform optimization, translational research.
• Organizational priorities: accelerate IND-enabling studies, expand GMP capacity, and strengthen global regulatory strategy.
• Patient commitment: improve access and affordability while maintaining global standards of safety and efficacy.

Further context on Keymed's strategic direction and corporate background can be found here: Keymed Biosciences Inc.: History, Ownership, Mission, How It Works & Makes Money

Keymed Biosciences Inc. (2162.HK) - Vision Statement

• Patient‑centricity: All programs and partnerships prioritize clinical benefit and real-world patient needs, guiding target selection, trial endpoints, and access strategies.
• Integrity: Ethical conduct, transparent reporting, and regulatory compliance underpin research, commercialization, and corporate governance.
• Adaptability: Agile R&D processes and iterative clinical development allow rapid responses to new science, changing standards of care, and emergent patient populations.
• Collaboration: Strategic alliances with academic centers, CROs, and industry partners accelerate translation from discovery to clinic and broaden global reach.
• Innovation: Sustained investment in novel modalities and precision approaches drives a robust pipeline and differentiating therapeutic candidates.

• Pipeline breadth - over 10 drug candidates across preclinical to clinical stages focused on diabetes, obesity, and related metabolic disorders.
• Clinical depth - multiple candidates in Phase I and Phase II, with at least several assets designed for chronic metabolic indications requiring long-term safety and efficacy data.
• R&D intensity - prioritizing reinvestment into research programs to advance first‑in‑class and best‑in‑class molecules.
• Global patient impact - programs structured to address large addressable markets measured in hundreds of millions of patients with metabolic diseases worldwide.

• Ticker: 2162.HK - public listing facilitates capital access for pipeline progression.
• Capital deployment: prioritizes R&D and strategic partnerships to de‑risk assets through clinical inflection points.
• Portfolio diversification: balanced mix of near‑term clinical programs and earlier discovery assets to sustain long‑term value creation.
• Partnership leverage: co-development and licensing are key levers to accelerate clinical development and broaden commercialization footprints.

• Ethical leadership and transparent governance frameworks ensure decisions align with patient safety and stakeholder trust.
• Cross‑functional collaboration between discovery, clinical development, regulatory affairs, and commercial teams accelerates go‑to‑market readiness.
• Talent strategy emphasizes scientific excellence, regulatory experience, and global development capabilities to support multicountry trials and launches.